保乳手术治疗早期老年乳腺癌的临床价值

目的探讨保乳手术治疗早期老年乳腺癌的临床价值。方法将我院近期收治的早期老年乳腺癌患者150例,随机分为治疗组和对照组,各75例,治疗组患者进行保乳手术,对照组患者进行传统手术,对比分析两组患者经过手术后临床疗效,以及生活质量等。结果治疗组患者的手术中出血量、拔引流管时间、总的引流量及术后并发症显著优于对照组患者(P<0.05),同时治疗组患者经手术治疗后其生活质量高于对照组患者(P<0.05)。结论相比于传统的手术保乳手术具有手术后恢复时间短、并发症少及患者生活质量高等方面的优势,在临床治疗上可以进行大力推广。     

The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib

Introduction Anaplastic lymphoma kinase (ALK) targeting drugs provide an important option for advanced non-small cell lung cancer patients with this distinct tumor type; however, there is considerable uncertainty as to which drug provides the optimal value after crizotinib treatment. This study estimated the cost-utility of alectinib vs ceritinib from a US payer perspective.

Methods A cost-utility model was developed using partition survival methods and three health states: progression-free (PF), post-progression (PP), and death. Survival data were derived from the key clinical trials (alectinib: NP28761 &; NP28673, ceritinib: ASCEND I and II). Costs included drugs, adverse events, and supportive care. Utilities were based on trial data and the literature. One-way and probabilistic sensitivity analyses (PSA) were performed to assess parameter uncertainty.

Results Treatment with alectinib vs ceritinib resulted in increases of 2.55 months in the PF state, 0.44 quality adjusted life-years (QALYs), and $13,868, yielding a mean cost/QALY of $31,180. In the PSA, alectinib had a 96% probability of being cost-effective at a willingness-to-pay of $100,000/QALY. Drivers of model results were drug costs and utilities in the PF health state. The ICER ranged from $10,600–$65,000 per QALY in scenario analyses, including a sub-group analysis limited to patients with prior chemotherapy and crizotinib treatment.

Conclusions Treatment with alectinib in ALK?+?crizotinib-treated patients increased time progression-free and QALYs vs ceritinib. The marginal cost increase was driven by longer treatment durations with alectinib. This model demonstrates that alectinib may be considered a cost-effective treatment after progression on crizotinib.     

综合治疗方案在中晚期宫颈癌中的应用

观察综合方案治疗中晚期宫颈癌的近远期疗效,探索这一治疗方案在中晚期宫颈癌治疗中的应用价值。     

乳腺癌术后患侧上肢PICC置管化疗的临床应用

目的探讨PICC在乳腺癌患者患侧上肢临床使用效果。方法确定健侧上肢无法置管,患侧上肢无肿胀,术中只结扎腋静脉的分支,对腋静脉没有影响的25例患者,实施患侧上肢PICC置管,置管后做好肢体及导管护理。结果 25例患侧置管患者,14例在贵要静脉置管,11例肘正中静脉置管,胸片显示：管尖端均进入上腔静脉中下端,留置时间为126～168d,6～8疗程。贵要静脉发生穿刺口感染1例,肘正中静脉发生静脉炎4例,经处理后症状改善,全部顺利完成化疗,无严重并发症发生,顺利拔管。结论正确评价患侧上肢血管,严格规范置管和导管维护,重视对患者宣教,乳腺癌患者患侧上肢可行PICC置管。     

中医辨证配合化疗治疗晚期肺癌临床分析

目的探究中医辨证配合化疗对晚期肺癌患者的临床治疗效果。方法将我院2011年1月～2012年1月接诊的53例晚期肺癌患者作为研究对象,随机分为研究组与对照组。对照组患者单纯采用化疗治疗,研究组则在对照组的基础上配合中医辨证治疗。对两组病患的治疗效果进行总结与对比。结果研究组治疗前平均分为58.45分,治疗后为71.35分,对照组治疗前平均分为58.13分,治疗后为49.63分;研究组27例患者半年的生存率为81.48%,一年的生存率为48.15%,对照组26例患者半年生存率为46.15%,一年生存率为15.38%;治疗效果上,研究组总有效率为40.74%,对照组总有效率为15.38%。结论对于晚期肺癌患者而言,采用中医辨证配合西医化疗治疗,除了可以提高患者对化疗的耐受性之外,还能明显提高患者的生存质量,当属一种值得临床推广及应用的治疗方法。     

浅谈单侧多中心性乳腺癌分析

目的:探讨单侧多中心性乳腺癌的特点及治疗方法。病灶多分布在同一象限或相邻象限,以浸润性导管癌为主,采用乳腺癌改良根治为主的综合治疗。     

Notes on some present day Questions regarding Mortality

Abstract

In the absence of any definite development of actuarial science in Great Britain which would be a suitable subject for this paper I considered that the most useful course would be to discuss some of the problems which are at present exercising my own mind, and no doubt the minds of many of my colleagues. Probably, many of these questions are akin to others which arise in other countries, so that their discussion at a meeting such as this may prove of mutual interest, while even if they are peculiar to ourselves, a disclosure of our doubts and difficulties will indicate the directions in which future developments may be expected. I must, however, emphasize that any views expressed are purely personal, and do not in any way pretend to represent a consensus of British actuarial opinion. Throughout this paper only Ordinary (as opposed to Industrial) business in considered.     

Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer

Abstract

Objective: Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitabine versus taxanes.

Methods: Women receiving first-line chemotherapy for MBC from 1998 to 2002 were identified from a hybrid North Carolina Medicaid-claims-tumour registry linked database and Medicare records, and were followed through to 2005 with claims data. Statistical t- and chi-square tests were used to compare baseline characteristics between patients who received first-line chemotherapy with capecitabine versus taxanes. Projected mean costs for 12 months continuous eligibility were estimated using an ordinary least squares linear regression. Overall cost impact of capecitabine after start of therapy was then examined using a multivariate log-linear regression model.

Results: While patients starting taxanes had significantly lower total costs in the pre-index year than patients starting capecitabine (mean: $20,042 vs. $35,538, p<0.001), in the post-index year, the patients on taxanes experienced significantly higher healthcare utilisation and associated costs compared to patients on capecitabine (mean: $43,353 vs. $35,842, p=0.0089). The differences were primarily attributable to lower expenses in chemotherapy related claims and fewer visit days to outpatient settings for patients on capecitabine. After adjustment with propensity scores and other confounders, the capecitabine group was associated with 32% lower healthcare costs compared to the taxane group (p=0.0001).

Conclusions: In this population-based study, women who received capecitabine as first-line treatment for MBC had significantly lower costs compared to women starting taxane therapy.     

论胶原蛋白对人类健康的特殊作用

胶原蛋白在人体中含量很多,过去一直被人们视为非常普通的物质而未加留意和重视。二十世纪七十年代以来,国际上对于胶原蛋白的研究相当活跃,取得了惊人的进展。现已发现,胶原蛋白具有提高免疫力、预防癌症、防治慢性病、促进细胞新陈代谢、提高钙的吸收力、消除便秘等功能,与人类健康不但息息相关,且具有非常重要的作用。     

88例食道癌术后胃肠减压的护理干预

目的:探讨食道癌术后胃肠减压的护理。方法:对88例食道癌术后患者胃肠减压期间,给予心理护理等一系列的护理措施。结果:所有患者中85例置管成功,有3例没有成功,成功率为96%,有2例出现了脱落,有1例出现了自行拔出胃管。结论:对患者进行有效的胃肠减压,这是确保手术成功的必要条件,护理工作中要密切观察患者的引流是否通畅,如发现问题要及时进行调整,使患者快捷痊愈。